CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Biolevate›
Library
Biolevate

Biolevate

Biolevate provides an evidence-grade AI platform for governed life sciences operations.

HQ
Sucy-en-Brie, FR
Founded
2024
Loading
Overview
Compare
Fundraising
Employees
News
Library

Biolevate - Library

Official pages and third-party coverage in one index.

biolevate.com·22 items across 17 mapped pages · Crawled Oct 1, 2026·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Product

6 pages
  1. Elevate human/pages/success-biocap
  2. Elevate human/solutions/regulatory-support
  3. Elevate human/solutions/evidence-planning-support
  4. Elevate human/solutions/target-drug-evidence-therapeutic-potential

Blog

1 page
  1. Blog/blog

Press

1 page
  1. Biolevate Raises €30 Million Series A/news/series-a-2026

    Biolevate announces its €30 million Series A and Boston office opening.

Careers & Hiring

2 pages
  1. Careers/pages/careers
  2. Job/careers/job

About

1 page
  1. Whoweare/pages/whoweare

Contact

2 pages
  1. Contactus/pages/contactus
  2. Elevate human/pages/contact-salon

Homepage

2 pages
  1. Homepage/

    Elevate human : Accelerating life sciences, empowering people

  2. Old Home/old-home

    Elevate human : Accelerating life sciences, empowering people

Privacy

1 page
  1. Cookiepolicy/pages/cookiepolicy

Terms & Conditions

1 page
  1. Legal/pages/legal

Not yet classified

1 page
  1. biolevate.com/

    Elevate human : Accelerating life sciences, empowering people

Coverage

4 items
  1. Akkodis and Biolevate Partner to Accelerate AI-Powered Scientific, Regulatory and Technical Documentation in Highly Regulated Industriessignalnewschicago.com/press-releases/117581/akkodis-and-biolevate-partner-to-accelerate-ai-powered-scientific-regulatory-and-technical-documentation-in-highly-regulated-industries/

    Akkodis and Biolevate announce a strategic partnership to accelerate AI-assisted scientific, regulatory, and technical documentation in highly regulated industries. The partnership launches first in France and Belgium on Biolevate’s ELISE platform.

    Sep 2026 · SignalNews ChicagoNews article

  2. Biolevate Raises €30 Million Series A & Opens Boston Office to Meet Surging Demandbiolevate.com/news/series-a-2026

    Biolevate raises a €30 million Series A co-led by RAISE France and Orange Ventures. The round includes MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures; the company says the funding accelerates international expansion, including the opening of a new Boston office, amid surging demand.

    Sep 2026 · BiolevateNews article

  3. Orange Ventures Invests in Biolevate to Expand Agentic AI in Life Sciencesinsidetelecom.com/orange-ventures-invests-in-biolevate-to-expand-agentic-ai-in-life-sciences/

    Orange Ventures invests in French health-tech startup Biolevate. Orange Business partners with Biolevate to expand trusted agentic AI across the life sciences. The partnership spans pharmaceutical research, clinical development, and regulatory processes.

    Sep 2026 · Inside TelecomNews article

  4. Biolevate’s raises €6M to helps medical writers keep up with the pace of new drugstechcrunch.com/2024/11/25/biolevates-raises-e6m-to-helps-medical-writers-keep-up-with-the-pace-of-new-drugs/

    Paris-based Biolevate raises a €6 million seed round led by EQT Ventures to support its platform for medical writers. The platform uses natural-language processing and visual document reading to help medical writers draft faster and keep up with the pace of new drugs.

    Nov 2024 · TechCrunchNews article